Phase II Clinical Trials CROs

Formerly Covance, Labcorp Drug Development provides comprehensive drug development services from early discovery through post-approval. One of the world's largest CROs with extensive nonclinical and clinical capabilities.

Global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. ICON specializes in clinical research with operations across 53 countries.

Integrated biopharmaceutical solutions company combining clinical development and commercial capabilities. Syneos offers end-to-end solutions from Phase I through product launch and beyond.

A leading global contract research organization acquired by Thermo Fisher Scientific. PPD provides comprehensive clinical development services including laboratory, data management, and regulatory services.

Global biopharmaceutical services company providing clinical research, regulatory consulting, and market access services. Parexel has supported the development of many blockbuster drugs.

Scientifically-driven, global, full-service clinical CRO providing Phase I-IV clinical development services. Medpace is known for its therapeutic expertise and operational efficiency.

Global CRO providing bioanalytical, clinical pharmacology, and Phase I-IV clinical trial services. QPS operates CLIA-certified bioanalytical laboratories supporting regulated studies.

Mid-size global CRO providing Phase I-IV clinical development services with expertise in CNS, cardiovascular, and metabolic disease therapeutic areas.

Clinical research organization providing Phase I-III clinical trial management, monitoring, and regulatory services with a focus on small-to-mid-size biotech and specialty pharma sponsors.

Japanese CRO group providing clinical development, data management, biostatistics, and regulatory affairs services across Japan, China, Korea, and Southeast Asia.

South Korean full-service CRO providing clinical development services from Phase I through post-marketing with bioanalytical capabilities and strong ties to Korean academic medical centers.

Asia-Pacific focused full-service CRO providing clinical trial management, data management, and biostatistics services with particular expertise in cardiovascular, renal, and diabetes trials.

Australian not-for-profit pharmaceutical company developing and registering medicines for neglected tropical diseases, providing regulatory and clinical development services for global health products.

Global CRO acquired by ICON in 2021. Provides full-service clinical development, data management, and strategic consulting across all major therapeutic areas.

Asia-Pacific specialist CRO providing full-service clinical development capabilities with deep expertise in the Asia-Pacific regulatory landscape.

Leading Australian Phase 1 clinical trials unit operating in Melbourne, Brisbane, and Minneapolis. Specializes in first-in-human, oncology Phase 1, and healthy volunteer studies with rapid enrollment timelines.

Perth-based clinical trial site and CRO specializing in Phase 1–3 studies across multiple therapeutic areas. Located at the Harry Perkins Institute of Medical Research.

Australian full-service CRO providing Phase 1–3 clinical trial management with expertise in biotech-focused programs. Known for the Australian Clinical Trial Notification (CTN) regulatory pathway advantage.

Specialty CRO focused on cardiometabolic clinical trials. Operates Phase 1–2 studies for obesity, diabetes, NASH/MASH, and cardiovascular endpoints with proprietary biomarker platforms.

Global clinical research and health data analytics company formed from the merger of IMS Health and Quintiles. Offers end-to-end clinical development, real-world evidence, and technology solutions.

Contract research organization spun off from Labcorp in 2023. Provides Phase 1–4 clinical development services, patient access solutions, and regulatory consulting globally.

Mid-size CRO specializing in clinical development for small and emerging biotech companies. Now part of Allucent, offering Phase 1–3 trial management and regulatory consulting.

UK-based specialist oncology CRO providing early-phase clinical trial management, tumour genomics, and biomarker-driven trial design for immuno-oncology programmes.

Central European CRO headquartered in Prague providing full-service Phase I-IV clinical trial management across the Czech Republic, Slovakia, Poland, and Hungary.

German CRO and FSP provider delivering clinical trial management, pharmacovigilance, and medical information services across the DACH region and Central Europe.

Frankfurt-based specialty CRO focusing on endocrinology and oncology clinical development with strong European regulatory expertise.

Clinical research division of India's major healthcare group, leveraging access to 30+ hospitals and diverse patient populations for multi-site Phase II-IV trials across therapeutic areas.

Full-service Indian CRO backed by the Manipal Group, offering end-to-end clinical development services from Phase I through Phase IV with particular expertise in BA/BE studies and oncology trials.

Ahmedabad-based CRO with a 350-bed Phase I clinical pharmacology unit, specializing in early-phase clinical trials, BA/BE studies, and bioanalytical services for global pharma clients.

Full-service boutique CRO with a purpose-built MHRA-accredited Phase I unit in South Wales. Specializes in early-phase clinical pharmacology, oncology, rare diseases, and respiratory conditions through to Phase III.

One of Europe's largest full-service CROs with a dedicated network of research sites across the UK, conducting global clinical studies from Phase I through Phase IV with particular strength in patient recruitment.

World leader in human challenge trials for infectious and respiratory diseases, operating from a purpose-built quarantine facility in London with 14+ validated infection models for RSV, influenza, and COVID-19.

Fully integrated German CRO/CDMO offering drug discovery, non-clinical studies, pharmaceutical analysis, GMP manufacturing, and early-phase clinical trials from facilities in Germany and France.

Global full-service CRO specializing in oncology, rare disease, and complex clinical trials across all development phases, with 2,900+ clinical research professionals operating in 100+ countries.

Mid-size global CRO with nearly 700 professionals across 50 countries, specializing in oncology, rare disease, and complex clinical programs with particular strength in dermatology and CNS.

Swedish CRO with a 12-bed first-in-human research unit at Uppsala University Hospital, specializing in Phase I and Phase II trials with approximately five FIH studies annually.

Danish biomarker CRO specializing in neoepitope biomarker technologies for tissue remodeling, conducting clinical trials in rheumatology, musculoskeletal, and metabolic disease with CAP-accredited laboratories.

Swiss full-service CRO operating in 56 countries with 3,000 staff, specializing in pivotal Phase II-III clinical trials in oncology, hematology, multiple sclerosis, and rare diseases.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

Leading Central and Eastern European full-service CRO operating across 30+ countries with 510+ staff and 1,700+ completed studies, expanded through acquisitions of Crown CRO, SSS International, and MKS Research.

Full-service clinical CRO headquartered in Oslo with a distinctive co-investment business model and offices across Scandinavia, UK, Germany, and Poland, specializing in oncology and rare diseases.

Full-service CRO with a dual-hub strategy across Eastern Europe and the Balkans, offering end-to-end clinical trial services for Phase I-IV studies with competitive patient recruitment timelines.

Full-service CRO based in Warsaw providing Phase I-IV clinical trial management, regulatory affairs, site management, and biometrics across Central and Eastern Europe.

Spanish full-service CRO and site management organization providing clinical trial management, regulatory affairs, and pharmacovigilance services in Spain, Italy, and Portugal.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

Global CRO with nearly 1,000 employees covering 30+ countries, providing full-spectrum multilingual clinical development from early phase through post-approval in oncology and CNS.

Technology-enabled mid-size clinical CRO offering Phase I-IV development services with particular strength in oncology, rare disease, and CNS therapeutic areas.

Integrated clinical research site organization operating 20+ dedicated research sites across the US, providing high-quality Phase I-IV clinical trial execution with rapid patient enrollment.

Full-service contract research and consulting organization providing clinical trial management, biostatistics, data management, and regulatory services with particular expertise in rare disease and pediatrics.

Integrated biopharmaceutical solutions company combining clinical development and commercial capabilities to accelerate customer success from Phase I through product launch.

Clinical research site in Phoenix conducting Phase I-IV clinical trials with particular strength in CNS, pain, and metabolic disease studies with rapid enrollment capabilities.

Contract research organization specializing in clinical research support for US government agencies including NIH, providing data management, biostatistics, and clinical operations for federally funded trials.

Multi-site clinical research organization conducting Phase I-IV trials with a network of dedicated research sites across the upper Midwest specializing in diverse therapeutic areas.

Japan's largest independent CRO providing end-to-end pharmaceutical development services including clinical operations, data management, regulatory affairs, and post-marketing surveillance across Asia.

Japanese full-service CRO with global operations providing clinical development from early phase through post-marketing with deep oncology and CNS expertise across Asia, Europe, and the US.

China's largest independent CRO providing comprehensive clinical development services from preclinical through post-marketing with operations across China, Asia, and globally.

Indian clinical CRO providing Phase I-IV clinical trials, bioanalytical services, and clinical pharmacology studies with dedicated Phase I units and bioanalytical laboratories.

South Korean CRO providing Phase I-IV clinical development, bioanalytical services, and regulatory consulting with particular expertise in simultaneous MFDS-FDA-EMA regulatory submissions.

South Korean CRO specializing in clinical trial management and data services for pharmaceutical companies developing products for both Korean and global regulatory submissions.

Singapore's national academic clinical research organization supporting investigator-initiated and industry-sponsored clinical trials across Southeast Asia with strong oncology expertise.

Australian pharmaceutical research company providing preclinical and clinical development services with expertise in inflammatory bowel disease and gastrointestinal therapeutic areas.

French clinical-stage gene therapy company and CRO specializing in CNS gene therapy development, providing clinical trial management for rare neurological diseases.

Leading IRB, IACUC, and consulting services provider for clinical and preclinical research, plus site management and performance optimization services.

Full-service CRO based near FDA headquarters with 25+ years of regulatory and clinical trial expertise including adaptive designs, BE/BA studies, and pharmacovigilance.

Oncology CRO founded by oncology thought-leaders specializing in Phase I and II immuno-oncology trials in North America and Europe.

Full-service CRO providing clinical research, biostatistics, data management, and regulatory services with particular expertise in ophthalmology, CNS, and rare disease.

Independent Australian full-service CRO specializing in pharmaceutical, medical device and biotechnology clinical trials, award-winning APAC CRO of the Year.

Full-service global CRO providing clinical development services across all phases with deep expertise in CNS, rare disease, and cardiovascular therapeutic areas and strong site networks.

Canadian full-service CRO providing clinical research services from Phase I through Phase IV with particular expertise in bioequivalence studies and pharmacokinetic trials.

Syneos Health's Korean operations providing full-service clinical development support for Korean and global pharmaceutical companies conducting trials in South Korea and APAC markets.

Mid-size global CRO acquired by Labcorp providing clinical development services from Phase I through Phase IV with operations across Europe, Asia, and the Americas.

World's leading ophthalmology-specialized CRO providing full-service clinical development from Phase I through Phase IV exclusively for ophthalmic therapeutics, devices, and surgical products.

French CRO providing Phase I-III clinical development services with particular expertise in metabolic disease, endocrinology, and cardiovascular trials across Europe.

US-based CRO specializing in rare disease and pediatric clinical trials, providing end-to-end trial management with deep expertise in orphan drug development and regulatory strategy.

PPD's Chinese clinical operations providing Phase I-IV clinical development, regulatory strategy, and site management for multinational and domestic pharmaceutical companies in Greater China.

Parexel's Indian operations providing clinical trial management, data management, biostatistics, and regulatory consulting for pharmaceutical companies conducting trials in India and South Asia.

European mid-size CRO providing clinical trial monitoring, project management, and regulatory services across Europe with a model combining outsourced and insourced clinical operations.

ICON's Japanese operations providing full-service clinical development for pharmaceutical companies conducting trials in Japan and supporting PMDA regulatory submissions.

Japanese CRO subsidiary providing clinical monitoring, data management, and pharmacovigilance services specializing in small-to-mid-size pharma and biotech sponsors across Asia.

China-based global CRO providing full clinical development services from Phase I through IV with strong site networks across China, Korea, and Southeast Asia.

Australian full-service CRO focused on early-phase clinical trials in oncology, rare disease, and dermatology, leveraging Australia's Clinical Trial Notification scheme for faster trial start-up.

IQVIA's Indian operations providing comprehensive clinical development, regulatory consulting, and healthcare analytics services for pharmaceutical companies across South Asia.

Mid-size CRO acquired by IQVIA providing boutique-level clinical development services with deep therapeutic expertise in oncology, CNS, and rare disease for small-to-mid-size biotech sponsors.

Chinese pharmaceutical company providing contract research and clinical development services for pharmaceutical companies seeking NMPA approvals in China.

Canadian CRO providing Phase II-IV clinical trial management, real-world evidence studies, and health economics consulting with 30+ years of experience in respiratory, rheumatology, and dermatology.

ICON's Australian operations leveraging Australia's CTN scheme for rapid Phase I trial initiation, supporting multinational sponsors with early-phase development in the APAC region.

Clinical operations arm of the former inVentiv Health (now Syneos Health) providing Phase I-IV trial management with particular expertise in dermatology and CNS therapeutic areas.

Specialty CRO focused on oncology and rare disease with 2,000+ professionals, known for biomarker-driven trial design, companion diagnostics, and translational research services.

Full-service CRO purpose-built for small and mid-size biotech, combining legacy of CATO Research, SMS Oncology, Pharm-Olam, and Nuventra into an integrated clinical development partner.

Clinical development and strategic resourcing organization providing full CRO services and functional service provider models to biopharma companies since 1994.

Tech-enabled next-generation CRO offering faster and lower-cost clinical trials powered by proprietary software, targeting biotech sponsors in dermatology, oncology, and ophthalmology.

Full-service oncology-focused CRO with 40+ years managing early-phase oncology studies for the National Cancer Institute and biopharma sponsors.

The only global full-service CRO focused exclusively on CNS drug development, with involvement in 22 FDA-approved CNS therapies across 13 indications.

Global tech-enabled full-service CRO with strength in government-sponsored trials, infectious disease, vaccines, ophthalmology, and rare disease clinical development.

Decentralized CRO enabling fully virtual and hybrid clinical trials through a proprietary Metasite platform, reducing site burden and improving patient access.

US-based CRO providing full-service Phase I-IV clinical trial support for small and mid-size pharma and biotech with expertise in CNS, oncology, and infectious disease.

IQVIA's Japanese subsidiary providing clinical operations, real-world data analytics, regulatory strategy and technology solutions with one of the largest clinical operations teams in Japan.

Physician-led Australian CRO offering full-spectrum clinical and non-clinical services with AI-driven operating model across Phase I-III for innovative biotechs.

Singapore-founded full-service CRO with operations across 12 Asia-Pacific markets, offering clinical trial management, regulatory affairs and data services.

Ahmedabad-founded full-service CRO and one of Asia's largest BA/BE and early-phase Phase I units, offering clinical, bioanalytical and biometric services across 4 countries.

India's original CRO founded in 1996 providing clinical trial operations, FSP services, data management, medical writing, biostatistics and pharmacovigilance across global programs.

Australia's original full-service CRO since 1987, managing clinical research across all phases and most therapeutic areas for pharma, biotech and medical device companies.

Clinical division of WuXi AppTec providing end-to-end Phase I-IV clinical trial services across China and Asia with expertise in NMPA, FDA and EMA regulatory submissions.

Parexel's Japanese arm offering full-service clinical development, regulatory consulting and market access services with deep PMDA submission expertise.

South Korea's first CRO founded in 1997, providing comprehensive Phase I-IV clinical development solutions including regulatory affairs, data management, pharmacovigilance and medical translation.

Seoul-based full-service Korean CRO with 400 clinical trial experts and experience across 1,600+ studies including 180+ global multi-center trials.

Ahmedabad-based mid-size CRO providing Phase I-IV clinical trials, bioequivalence studies, and bioanalytical services to Indian and global generic pharma companies.

Bangalore-based CRO subsidiary of Biocon offering early-phase clinical trials, bioequivalence studies, bioanalytical testing and Phase II-IV services with expertise in biosimilars.

Germany-based mid-size CRO providing early-phase clinical trials (Phase I/IIa), bioanalysis, DMPK, and translational medicine services from facilities in Neu-Ulm and Berlin.

Munich-based mid-size CRO providing Phase I-IV clinical trial management, regulatory consulting, pharmacovigilance, and medical affairs across Europe and Asia.

UK-headquartered global mid-size CRO (now part of LabCorp/Covance) with deep expertise in oncology, rare diseases, and paediatric clinical trials across 30+ countries.

Munich-based specialty CRO focused on medical device and in vitro diagnostic clinical studies, providing regulatory consulting, study monitoring, and clinical evaluation reports across Europe.

Canadian full-service CRO specialising in clinical trials and regulatory support for nutraceutical, cannabis, and natural health product industries.

Mid-size full-service global CRO offering integrated bioanalytical lab services alongside Phase I-IV clinical trial management with a focus on CNS, cardiovascular, and rare disease.

National clinical research coordinating body in Singapore established by A*STAR and MOH, offering study design, project management, data management, and biostatistics to pharma and academic sponsors.

World's leading site management organization with 90+ integrated research sites and 220+ investigators across the US, specializing in general medicine, vaccines, and infectious disease trials.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

Clinical trial arm of Frontage Laboratories providing Phase I-III services with integrated bioanalytical capabilities, bridging bioanalytical strength with full clinical execution.

Phase I-III oncology CRO providing clinical trial management with deep oncology expertise for small and mid-size pharma and biotech sponsors.

Japanese digital health and clinical research subsidiary of M3 Inc., leveraging its physician panel of 300,000+ doctors for clinical trial site identification and recruitment in Japan.

South Korea's largest clinical CRO and Tigermed subsidiary, delivering full-scope clinical services with 1,200+ successful projects across pharmaceuticals, biotech, and medical devices.

Greater China operations of Australian CRO Novotech, providing full-service clinical trial management across mainland China, Hong Kong and Taiwan with NMPA submission expertise.

Taipei-based drug development company and CRO specializing in oncology, running Phase I-III clinical trials for new cancer therapies and out-licensing proprietary pipeline assets.

Full-service Australian CRO delivering clinical research services across Australia and New Zealand, supporting sponsors through Phase I-IV development.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

Hyderabad-headquartered pharmaceutical CRO with dedicated clinical trials division providing drug discovery, early-phase clinical, and regulatory support with strong CNS expertise.

Israeli CRO specialising in clinical trial management, biostatistics, and regulatory affairs with expertise across Phase I-IV studies in oncology and rare diseases.

Singapore-based global CRO consulting organisation assisting clients from clinical development through commercialisation with a focus on Asia-Pacific market access.

Melbourne-founded CRO supporting small and mid-sized biotech companies across all clinical development stages including regulatory affairs, biometrics, and manufacturing scale-up.

Hyderabad-based publicly listed contract research and testing organisation offering integrated preclinical, clinical, and cGMP laboratory services for pharmaceutical companies worldwide.

India-based integrated CDMO and CRO providing API R&D, formulation development, bioanalytical services, and Phase I-IV clinical research from facilities in Hyderabad.

Hyderabad-based mid-size CRO operating across India, the Philippines, Thailand, Vietnam, and the Middle East, providing Phase I-IV clinical trial services and regulatory affairs.

Bangalore-based Indian CRO specialising in Phase I-IV clinical trials, bioequivalence studies, and regulatory affairs for domestic and international pharmaceutical companies.

Glasgow-founded, India-expanded full-service CRO providing clinical trial management, site management, and regulatory services across Asia-Pacific, Europe, and North America.

Nanjing-based clinical CRO and Pharmaron subsidiary providing one-stop clinical development services in China including regulatory affairs, clinical operations, pharmacovigilance, and bioanalysis.

Shanghai-based specialised clinical CRO providing full clinical development services in China and APAC with expertise in navigating NMPA regulatory pathways for multinational pharmaceutical companies.

Taiwan and China-focused CRO providing clinical development, regulatory strategy, and bioanalytical services with expertise in NMPA/TFDA dual-track submissions for sponsors entering Greater China.

US-Korea bridge CRO providing early-phase clinical and regulatory services tailored for Korean life science companies entering the US FDA pathway.

The first CRO established in Turkey, providing clinical and epidemiological research management to national and international pharmaceutical companies since 1997.

Istanbul-based Turkish CRO offering Phase I-IV clinical trials, bioequivalence studies, medical device trials, and electronic data capture services.

Ankara-based Turkish CRO specialising in bioequivalence and bioavailability study management, clinical operations, data management, and medical writing for multinational sponsors.

Full-service CRO headquartered in Dubai covering 31 countries across the Middle East and Africa with clinical operations, regulatory affairs, pharmacovigilance, and data management services.

Regional full-service CRO headquartered in Riyadh providing clinical trial monitoring and pharmaceutical consultancy across Egypt, Lebanon, Jordan, Gulf States, and Saudi Arabia.

CRO purpose-built for first-in-human clinical trials for MedTech, biopharma, and radiopharma startups across Latin America, operating in 10 countries.

Buenos Aires-based full-service Latin American CRO with operations across Argentina, Chile, Uruguay, Brazil, Peru, Mexico, and Colombia, covering Phase I-IV studies.

Monterrey-headquartered CRO operating across Mexico, Argentina, Colombia, and Brazil with 20+ years of clinical research experience merging high-efficiency standards with academic scientific rigour.

Mexico City-based CRO and leading provider of decentralised clinical trial home visit services, patient recruitment, and community research site networks across 22 Latin American countries.

The first South African full-service CRO providing Phase I-IV clinical trial management across Southern Africa and other African regions since 2007.

Kenya-founded niche full-service CRO specialising in vaccine, drug, and medical device clinical trials across sub-Saharan Africa with in-country teams in Kenya, Tanzania, Uganda, South Africa, and Ghana.

Cotonou-based African CRO with a unique West, Central, and East Africa footprint providing clinical trial site management, pharmacovigilance, data management, and market research services.

Tunis-based CRO covering most African countries, offering clinical research services, WHO-certified bioequivalence studies, regulatory submissions, pharmacovigilance, and pharmaceutical training.

Mission-driven global CRO (formerly FHI Clinical) with 50+ years of heritage managing complex clinical research in resource-limited settings across Africa, Asia, Latin America, and North America.

Belgium-based specialty CRO focused on epidemiology and vaccine development with local hubs in South Africa, Ghana, Kenya, and Morocco, having conducted 500+ studies in 20+ African countries.

US-based clinical-stage CRO arm specialising in endocrinology and cortisol-modulation therapeutics with expertise in Phase I-III metabolic and CNS clinical trials.

Nantes-based French CRO specialising in CNS, sleep medicine, and neuroscience clinical trials with proprietary EEG/PSG expertise and Phase I-II clinical pharmacology capabilities.

Full-service mid-size CRO specialising in rare diseases, transplantation, nephrology, and immunology across Phase I-IV trials.

Mid-size full-service global CRO offering Phase I-IV clinical trial management with strong coverage across emerging markets in Africa, Latin America, and Eastern Europe.

Phase I-III CRO and integrated research site network specialising in CNS, pain, obesity, and metabolic disease with wholly-owned clinical units in California.

Regulatory affairs and clinical development consultancy providing full-service FDA/EMA submission support, pharmacovigilance, and clinical trial management for small pharma and biotech.

Full-service CRO founded on biostatistics and data science excellence, supporting Phase I-IV trials across rare disease, immunology, and ophthalmology from Research Triangle Park.

Delhi-based Indian CRO providing regulatory and clinical trial management services across pharma, medical devices, and nutraceuticals.

Indian full-service CRO with offices in India, USA, UAE, and Hungary delivering Phases I-IV trials and real-world evidence studies across 18+ therapeutic areas.

Bangalore-based CRO specialising in medical device clinical validations, nutraceutical studies, and Phase I-IV pharmaceutical trials across India.

Pioneer Japanese CRO founded in 1982 providing one-stop pharmaceutical development services from early-phase through post-marketing activities in Japan and Asia.

Japanese CRO established in 1989 offering full CRO and SMO services in Japan and Vietnam through its Asia Clinical Trial Support Alliance network.

Clinical research division of South Korea's Ildong Pharmaceutical group, conducting domestic and international Phase I-IV studies with access to major Korean academic medical centres.

Vietnam's dedicated CRO/SMO founded by Japan's SRD Group, applying Japanese GCP expertise to support clinical trials at Vietnamese research hospitals.

Vietnam's first locally established and Ministry of Health-approved CRO providing clinical trial management and site support across Vietnamese hospitals.

Spain-based full-service European CRO specialising in Phase I-IV clinical trial management across EU member states with expertise in regulatory affairs and site monitoring.

UK-based Phase I-IV site network and CRO operating multiple dedicated clinical research centres across Northern England for healthy volunteer and patient population studies.

Full-service CRO headquartered in Bangalore supporting Phase II-IV pharmaceutical, biotechnology, and medical device trials across India.

Canadian specialty CRO focused exclusively on gastrointestinal disease clinical trials with proprietary central reading and histopathology services for IBD and liver disease.

French mid-size CRO specialising in Phase I-III clinical trials, biostatistics, and regulatory affairs with offices in Paris and North Africa.

Croatian full-service CRO providing Phase I-IV clinical trial management across Central and Eastern Europe with expertise in bioequivalence studies.

Belgian mid-size CRO providing clinical trial management, medical monitoring, and pharmacovigilance services across the EU with particular strength in oncology and rare disease.

Danish CRO focused on Scandinavian and Nordic clinical trial management, site selection, and regulatory submissions for pharma and medical device sponsors.

ISO 9001-certified full-service CRO with offices in Australia, Singapore, and India providing Phase I-IV trial management across the Asia-Pacific region.

Australian boutique CRO specialising in early-phase and first-in-human MedTech clinical trials across Australia, New Zealand, and the USA.

Australian CRO helping global pharma and biotech leverage the regulatory and cost advantages of clinical trials in Australia and New Zealand.

Independent New Zealand clinical research company conducting Phase I-IV trials with specialist early-phase capabilities and access to New Zealand's rapid ethics approval system.

Israel-based CRO with deep expertise in the Israeli pharmaceutical, medical device, and healthcare industry delivering clinical trial management for international sponsors.

Israeli CRO with 20+ years of experience providing clinical trial services for pharmaceutical, biotechnology, and medical device companies seeking Israel as a trial site.

Privately owned Israeli CRO providing clinical trial services for pharmaceutical and medical device companies targeting the Israeli market.

Israel's leading full-service CRO and clinical research training centre delivering clinical trial management solutions across pharmaceutical, device, and biotech sectors.

Regional full-service CRO established in Egypt conducting international clinical trials, real-world evidence, and health economic studies across the Middle East and North Africa.

Leading MEA and Pakistan CRO with 140+ employees that has conducted 300+ clinical trials in 35 countries spanning the Middle East, Africa, Pakistan, and the Eurasian Economic Union.

UAE's CRO headquartered under M42 Abu Dhabi, specialising in real-world evidence and comprehensive clinical trials across all therapeutic domains in the Gulf region.

Turkish full-service CRO providing clinical trial management, data management, pharmacovigilance, and regulatory affairs for Phase II-IV trials across Turkey and the broader Eurasian region.

Istanbul-based Turkish CRO offering clinical project management, site monitoring, regulatory submissions, and pharmacovigilance services across Turkey and the Balkans.

Lagos-based pioneer indigenous African CRO delivering Phase I-IV clinical trials with a focus on vaccines, neglected tropical diseases, oncology, and rare diseases across Sub-Saharan Africa.

West Africa-based CRO providing streamlined and cost-effective clinical trial solutions to global CROs, pharmaceutical, and medical device companies operating in Africa.

Nigerian contract research organisation providing clinical trial support, site management, data management, and regulatory affairs services for pharmaceutical sponsors in West Africa.

Latin America's first Academic Research Organisation affiliated with the Federal University of Sao Paulo, leading international multicentre studies in cardiology and infectious disease.

High-performance Brazilian clinical research CRO now part of QIMA Life Sciences, specialising in bioequivalence, Phase I-III trials, and ANVISA regulatory strategy.

Retina-specialty CRO with offices across Latin America, Asia, and Australia supporting clinical trials in 18+ countries for ophthalmic and rare disease indications.

Mid-size US CRO providing full-service Phase I-IV clinical trial management with expertise in oncology, rare disease, and CNS across 50+ countries.

California-based clinical CRO providing Phase I-III trial management, monitoring, and project oversight for emerging biotech and small pharma sponsors.

Pennsylvania-based dermatology and aesthetics specialty CRO providing Phase I-IV clinical trial management and site services for topical, injectable, and device-based products.

San Diego-based CRO specialising in dermatology clinical trials with proprietary non-invasive skin sampling technology for melanoma and inflammatory skin disease studies.

Specialty CRO focused exclusively on CNS clinical trials, neurocognitive endpoint assessments, and central rater training for Phase I-III neuropsychiatric studies.

Swiss/German full-service CRO providing Phase I-IV clinical trial management, regulatory consulting, and medical writing with offices across Germany, Austria, and Switzerland.

Turkish-German CRO providing Phase I-III clinical trial management, biostatistics, and regulatory consulting with focus on bridging European and Turkish markets.

California-based mid-size CRO providing full-service Phase I-III clinical trial management with deep expertise in oncology, rare disease, and CNS for emerging biotech.

US-based site management organisation providing clinical trial site identification, feasibility, start-up, and monitoring services for pharma and biotech sponsors.

US-India hybrid CRO providing clinical trial management, regulatory affairs, pharmacovigilance, and medical writing with cost-effective offshore delivery from India.

New Jersey-based mid-size CRO and FSP provider offering clinical operations, data management, and regulatory services across 40+ countries.

Miami-based full-service CRO specialising in complex and rare disease clinical trials with deep regulatory expertise for accelerated and breakthrough therapy designations.

Chinese CRO-turned-biotech providing clinical development services with deep oncology expertise, operating a portfolio of discovery through Phase III programs in solid tumors and hematological malignancies.

Thai royal research institute conducting preclinical and clinical research in oncology, environmental toxicology, and natural products with GLP-certified laboratory facilities.

Clinical research division of Brazil's largest national pharmaceutical company, conducting Phase I-IV clinical trials across 10+ Brazilian sites with particular expertise in generics and biosimilars.

Buenos Aires-based CRO providing Phase II-IV clinical trial management across Argentina, with strong site networks in cardiology, endocrinology, and rheumatology.

Bogota-based Colombian CRO providing clinical trial management, regulatory affairs, and pharmacovigilance services across the Andean region including Colombia, Peru, and Ecuador.

Riyadh-based Saudi CRO providing clinical trial management, regulatory consulting, and pharmacovigilance services across the GCC region with SFDA regulatory expertise.

Kenya Medical Research Institute's clinical trials unit conducting Phase I-III vaccine, malaria, HIV, and TB studies across multiple Kenyan sites in partnership with global funders.

Osaka-based clinical CRO specializing in medical device and diagnostic clinical trials in Japan, providing regulatory consulting, site management, and data management services under PMDA guidelines.

Clinical development arm of CJ HealthCare, providing Phase I-IV clinical trial management, BA/BE studies, and regulatory support services across South Korea with access to CJ's hospital network.

Seoul-based niche CRO specializing in dermatology and cosmetic clinical trials, providing IRB-approved study design, site management, and regulatory filing for K-beauty and pharmaceutical skincare products.

Philippine government research institute conducting clinical trials in tropical and infectious diseases including dengue, TB, and malaria, serving as a WHO-recognized reference laboratory.

Mexico City-based CRO specializing in CNS and psychiatry clinical trials across Latin America, with established investigator networks in Mexico, Colombia, and Chile.

Academic CRO affiliated with Stellenbosch University conducting TB, HIV, and respiratory clinical trials in the Western Cape, with GCP-accredited clinical pharmacology unit.

Johannesburg-based South African research institute conducting large-scale TB and HIV clinical trials across multiple African sites, with capabilities in vaccine trials and epidemiological studies.

Accra-based Ghanaian CRO specializing in vaccine clinical trials and infectious disease research across West Africa, with established relationships with WHO and GAVI-funded programs.

Melbourne-based CRO specializing in Phase I-IIa first-in-human studies, offering rapid trial startup under Australia's CTN scheme with access to leading Australian clinical pharmacology units.

Academic CRO based at Griffith University on the Gold Coast, conducting clinical trials in metabolic disease, sports medicine, and natural health products under TGA regulatory framework.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Mannheim-based German CRO providing clinical trial management, pharmacovigilance, and medical affairs services across Europe with particular expertise in cardiovascular and CNS indications.

Lisbon-based CRO providing clinical trial management, regulatory affairs, and medical writing services across Iberia and Latin America, with particular expertise in medical devices and diagnostics.

Stockholm-based Nordic CRO providing clinical trial management, biostatistics, and regulatory support for Phase I-IV studies across Scandinavian countries with EMA and FDA regulatory experience.

Gainesville, Florida-based dermatology and wound care CRO providing Phase I-IV clinical trials, photoprotection testing, and clinical pharmacology services for topical drug products.

New Jersey-based dermatology and personal care CRO conducting clinical trials, product testing, and consumer perception studies for pharmaceutical, cosmetic, and OTC skincare products.

Hamburg-based academic CRO affiliated with University Medical Center Hamburg-Eppendorf, conducting Phase I-III clinical trials with particular expertise in oncology and infectious disease.

Malaysian office of Novotech, Asia-Pacific's largest CRO, providing clinical trial management, regulatory affairs, and site management for Phase I-IV studies across Malaysia and ASEAN markets.

Ho Chi Minh City-based Vietnamese CRO providing Phase II-IV clinical trial management, BA/BE studies, and regulatory consulting for pharmaceutical companies entering the Vietnamese market.

Academic CRO affiliated with Taipei Medical University and three teaching hospitals, conducting Phase I-III clinical trials across oncology, neurology, and traditional Chinese medicine integration studies.

Lahore-based Pakistani CRO providing Phase II-IV clinical trial management, BA/BE studies, and pharmacovigilance services with access to Pakistan's large treatment-naive patient populations.

Dhaka-based CRO providing clinical trial management and bioequivalence studies for Bangladesh's pharmaceutical industry, one of the largest generic drug markets in South Asia.

Prague-based dedicated clinical trial site providing centralized patient recruitment and Phase II-IV trial conduct for global sponsors, part of the Synexus (now Acurian) network of research sites.

Bucharest-based Romanian CRO providing Phase I-IV clinical trial management, medical writing, and pharmacovigilance across Eastern Europe with access to Romania's large hospital networks.

Budapest-based CRO providing full-service clinical trial management across Hungary and Central Europe, with capabilities in oncology, rare disease, and biosimilar clinical programs.

Belgrade-based Serbian CRO providing clinical trial management, monitoring, and regulatory support for Phase II-IV studies across the Western Balkans region.

Paris-based European CRO providing clinical operations, pharmacovigilance, and regulatory affairs services across 40+ countries with particular strength in oncology and rare disease.

Madrid-based Spanish CRO providing full-service Phase I-IV clinical trial management, medical affairs, and pharmacovigilance across Iberian and Latin American markets.

Indian medical imaging and cardiac safety CRO providing centralized ECG reading, imaging endpoint adjudication, and eClinical technology services for global clinical trials.

Nairobi-based East African CRO providing Phase II-III clinical trial management and site coordination for infectious disease, vaccine, and maternal health studies across Kenya, Uganda, and Tanzania.

Milan-based Italian CRO providing clinical trial management, monitoring, and pharmacovigilance services across Southern Europe with expertise in medical devices and dermatology trials.

Cincinnati-based full-service CRO providing Phase I-IV clinical trial management, clinical pharmacology, and regulatory consulting services for pharmaceutical and biotech sponsors worldwide.

Full-service, technology-enabled oncology-focused CRO serving biotechnology and pharmaceutical companies across all clinical phases from Wilmington, Delaware.

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

Specialty CRO with 20+ years of dermatology, aesthetics, gastroenterology, and inflammation clinical trial expertise across the US, Europe, and Australia.

Fully integrated dermatology-dedicated CRO providing nonclinical through Phase III development services exclusively for skin disease products since 1997.

UK-based specialist CRO for ophthalmic and contact lens clinical trials, providing study design, clinical monitoring, and regulatory support for eye care medical devices and pharmaceutical products.

Full-service CRO integrating translational sciences, clinical pharmacology, bioanalysis, and regulatory strategy from preclinical through Phase IV development.

Europe's first specialist CRO dedicated to psychedelic compound clinical research, providing full-service trial design and execution for novel psychiatric treatments in the UK.

Innovation CRO purpose-built for medical device and IVD development, delivering integrated regulatory, clinical, and laboratory services across cardiovascular, neurological, and ophthalmic indications.

Global CRO built exclusively for MedTech, integrating regulatory strategy, clinical development, and market access reimbursement for device and IVD programs from the Netherlands since 1988.

MedTech CRO formed by the 2020 merger of Regulatory and Quality Solutions and Maetrics, delivering 40+ years of medical device regulatory, clinical, laboratory, and reimbursement expertise.

European full-service CRO formed by the 2024 merger of palleos healthcare and OCT Clinical, covering Western and Eastern Europe across 29 therapeutic areas from Wiesbaden, Germany.

Slovak-founded global full-service CRO with integrated clinical supply chain and depot network spanning Europe, North America, LATAM, APAC, and South Africa.

Global full-service CRO founded in 1995 with strong Asia-Pacific and European presence, expanded via acquisition of CROMSOURCE for deeper European clinical operations.

North America's largest integrated research organization with 40+ wholly owned clinical sites across Canada and the US, conducting Phase I-IV trials across 35+ therapeutic areas.

Next-generation decentralized CRO from London using a proprietary clinical trial platform to deliver faster, more efficient trials in cardiovascular, oncology, and ophthalmology.

Hamburg-based dermatology specialty CRO established in 1992, providing regulatory consulting and Phase I-IV clinical trial management for pharmaceutical, device, and cosmetic dermatology products.

Eastern and Central European CRO founded in 2005, providing Phase I-IV and bioequivalence services in oncology and infectious disease across 20+ countries.